Adial Pharmaceuticals Inc (ADIL) - Net Assets
Based on the latest financial reports, Adial Pharmaceuticals Inc (ADIL) has net assets worth $3.72 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.23 Million) and total liabilities ($1.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore Adial Pharmaceuticals Inc operating cash flow efficiency to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.72 Million |
| % of Total Assets | 71.11% |
| Annual Growth Rate | 41.57% |
| 5-Year Change | 50.42% |
| 10-Year Change | N/A |
| Growth Volatility | 63.72 |
Adial Pharmaceuticals Inc - Net Assets Trend (2015–2025)
This chart illustrates how Adial Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore Adial Pharmaceuticals Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Annual Net Assets for Adial Pharmaceuticals Inc (2015–2025)
The table below shows the annual net assets of Adial Pharmaceuticals Inc from 2015 to 2025. For live valuation and market cap data, see ADIL market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $5.28 Million | +29.70% |
| 2024-12-31 | $4.07 Million | -0.38% |
| 2023-12-31 | $4.08 Million | +24.63% |
| 2022-12-31 | $3.28 Million | -6.59% |
| 2021-12-31 | $3.51 Million | -12.00% |
| 2020-12-31 | $3.99 Million | -44.18% |
| 2019-12-31 | $7.14 Million | +60.78% |
| 2018-12-31 | $4.44 Million | +545.22% |
| 2017-12-31 | $-997.55K | -863.88% |
| 2016-12-31 | $-103.49K | -163.44% |
| 2015-12-31 | $163.15K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Adial Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8045444900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.11K | 0.02% |
| Other Components | $95.25 Million | 1805.15% |
| Total Equity | $5.28 Million | 100.00% |
Adial Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Adial Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rainbow Rare Earths Limited
LSE:RBW
|
$2.04 Million |
|
Ferrexpo PLC
LSE:FXPO
|
$2.05 Million |
|
Brown Advisory US Smaller Companies PLC
LSE:BASC
|
$2.05 Million |
|
Aker Carbon Capture ASA
OL:ACC
|
$2.05 Million |
|
Knights Group Holdings plc
LSE:KGH
|
$2.03 Million |
|
BLAZE Minerals Ltd
AU:BLZ
|
$2.03 Million |
|
Lixiang Education Holding Co Ltd
NASDAQ:LXEH
|
$2.03 Million |
|
AFC Energy plc
LSE:AFC
|
$2.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adial Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,068,084 to 5,276,458, a change of 1,208,374 (29.7%).
- Net loss of 7,977,171 reduced equity.
- New share issuances of 3,658,552 increased equity.
- Other factors increased equity by 5,526,993.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.98 Million | -151.18% |
| Share Issuances | $3.66 Million | +69.34% |
| Other Changes | $5.53 Million | +104.75% |
| Total Change | $- | 29.70% |
Book Value vs Market Value Analysis
This analysis compares Adial Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.30x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.11x to 0.30x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $21.32 | $2.39 | x |
| 2016-12-31 | $-13.54 | $2.39 | x |
| 2017-12-31 | $-113.88 | $2.39 | x |
| 2018-12-31 | $583.23 | $2.39 | x |
| 2019-12-31 | $452.97 | $2.39 | x |
| 2020-12-31 | $199.89 | $2.39 | x |
| 2021-12-31 | $117.94 | $2.39 | x |
| 2022-12-31 | $77.06 | $2.39 | x |
| 2023-12-31 | $71.66 | $2.39 | x |
| 2024-12-31 | $5.47 | $2.39 | x |
| 2025-12-31 | $7.89 | $2.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adial Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -151.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.26x
- Recent ROE (-151.18%) is above the historical average (-249.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -501.39% | 0.00% | 0.00x | 1.33x | $-834.31K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-409.85K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.04 Million |
| 2018 | -261.89% | 0.00% | 0.00x | 1.06x | $-12.08 Million |
| 2019 | -120.32% | 0.00% | 0.00x | 1.08x | $-9.31 Million |
| 2020 | -272.46% | 0.00% | 0.00x | 1.38x | $-11.26 Million |
| 2021 | -553.72% | 0.00% | 0.00x | 2.18x | $-19.77 Million |
| 2022 | -388.57% | 0.00% | 0.00x | 1.75x | $-13.06 Million |
| 2023 | -171.47% | 0.00% | 0.00x | 1.16x | $-7.41 Million |
| 2024 | -324.41% | 0.00% | 0.00x | 1.24x | $-13.60 Million |
| 2025 | -151.18% | 0.00% | 0.00x | 1.26x | $-8.50 Million |
Industry Comparison
This section compares Adial Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,677,567
- Average return on equity (ROE) among peers: -58.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adial Pharmaceuticals Inc (ADIL) | $3.72 Million | -501.39% | 0.41x | $2.04 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid p… Read more